Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulio Cavalli

Showing results (41-50 of 136) with videos related to

Pageof 14
Sort By:
Annals of Internal Medicine|September 7, 2020
A Novel Histiocytosis With Synovial and Skin InvolvementGiulio Cavalli, Giacomo De Luca, Claudio Doglioni, et al.
Clinical and Experimental Rheumatology|March 29, 2022
Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's diseaseCorrado Campochiaro, Nicola Farina, Alessandro Tomelleri, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|October 27, 2020
Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?Francesco Benedetti, Mario Mazza, Giulio Cavalli, et al.
Annals of the Rheumatic Diseases|February 12, 2013
The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new casesGiulio Cavalli, Barbara Guglielmi, Alvise Berti, et al.
Annals of the Rheumatic Diseases|December 11, 2019
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester diseaseCorrado Campochiaro, Giulio Cavalli, Nicola Farina, et al.
Frontiers in Immunology|February 25, 2017
Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart FailureGiulio Cavalli, Marco Foppoli, Luca Cabrini, et al.
International Journal of Cardiology|June 1, 2017
QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic riskGiacomo De Luca, Silvia Laura Bosello, Giovanni Canestrari, et al.
Journal of Leukocyte Biology|February 15, 2020
Erdheim-Chester disease: An in vivo human model of Mϕ activation at the crossroad between chronic inflammation and cancerGiulio Cavalli, Lorenzo Dagna, Riccardo Biavasco, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|January 4, 2021
Correction to: Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?Francesco Benedetti, Mario Gennaro Mazza, Giulio Cavalli, et al.
Seminars in Arthritis and Rheumatism|February 24, 2020
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritisCorrado Campochiaro, Alessandro Tomelleri, Silvia Sartorelli, et al.
Pageof 14

Showing results (41-50 of 136) with videos related to

Sort By:
Pageof 14
Annals of Internal Medicine|September 7, 2020
A Novel Histiocytosis With Synovial and Skin InvolvementGiulio Cavalli, Giacomo De Luca, Claudio Doglioni, et al.
Clinical and Experimental Rheumatology|March 29, 2022
Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's diseaseCorrado Campochiaro, Nicola Farina, Alessandro Tomelleri, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|October 27, 2020
Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?Francesco Benedetti, Mario Mazza, Giulio Cavalli, et al.
Annals of the Rheumatic Diseases|February 12, 2013
The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new casesGiulio Cavalli, Barbara Guglielmi, Alvise Berti, et al.
Annals of the Rheumatic Diseases|December 11, 2019
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester diseaseCorrado Campochiaro, Giulio Cavalli, Nicola Farina, et al.
Frontiers in Immunology|February 25, 2017
Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart FailureGiulio Cavalli, Marco Foppoli, Luca Cabrini, et al.
International Journal of Cardiology|June 1, 2017
QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic riskGiacomo De Luca, Silvia Laura Bosello, Giovanni Canestrari, et al.
Journal of Leukocyte Biology|February 15, 2020
Erdheim-Chester disease: An in vivo human model of Mϕ activation at the crossroad between chronic inflammation and cancerGiulio Cavalli, Lorenzo Dagna, Riccardo Biavasco, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|January 4, 2021
Correction to: Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?Francesco Benedetti, Mario Gennaro Mazza, Giulio Cavalli, et al.
Seminars in Arthritis and Rheumatism|February 24, 2020
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritisCorrado Campochiaro, Alessandro Tomelleri, Silvia Sartorelli, et al.
Pageof 14